Background: Breast cancer is the most common cancer found in women worldwide. In 2012, more than 50% of breast cancer patients in Cipto Mangunkusumo Hospital were diagnosed with advanced breast cancer. The 5 years survival rate in stage 3 breast cancer patients is 72 % and only 22% in stage 4 patients even after receiving adequate treatment. CD105 (endoglin) is expressed significantly inactivated endothelial cells in culture and in tumormicrovessels.

 

Methods: A retrospective cohort analysis data was retrieved from patient medical records Dharmais Cancer Hospital from 2011-2014 were studied. A simple random sampling obtained a total of 32 patients. Statistical analysis was performed using univariate and multivariate analysis SPSS version 17.0 and medcalc.

 

Results: The relationship between the CD105 and the survival rate is: crude HR 1.724 (95% CI 0.693 to 4.288) p=0.241. The median survival rate of the CD105 positive group is higher than the negative group which is 1113 days and 794 days respectively. Negative CD105 has higher survival rate compared to positive CD105 group in luminal A, therapy modalities and metastasis. There is a significant relationship between CD105 and the clinical pathology (p=0.034). There are more subjects with negative CD105 than positive CD105 in either grade IIIB or grade IV (69% and 63.3%). CD105 is inversely correlated with hormonal receptors and there is a significant relationship between PR and CD105 (p=0.042). There are 71.8% subjects with either HER2 or CD105 negative and 60% of the patients showed CD105 and HER2 positive, while there are more positive CD105 in either KI67 positive or negative.

 

Conclusion: CD 105 expression has clinical relevance in predicting survival rate in advanced breast cancer but not in statistical findings, therefore it is trivialto be used as a prognostic factor.